BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 7, 2007
View Archived Issues
Nektar Keeps Promotion Rights In $175M Deal On Amikacin Drug
Nektar Therapeutics Inc. is getting $50 million up front and retaining co-promotion rights in a deal with Bayer HealthCare AG covering its Phase II inhaled amikacin product for pneumonia. (BioWorld Today)
Read More
BioCryst Adds $65M Privately To Boost Pipeline Development
Read More
Another TRP Family Member Charged With Causing Pain
Read More
Curis Raises $13 Million To Support Cancer Programs
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Appointments And Advancements
Read More